Expertise in
18
conditions

Dr. Boyu Hu

Hematology
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
On Staff At
Accepting New Patients
Expertise in
18
conditions
1950 Circle Of Hope Dr, 
Salt Lake City, UT 

Overview

Boyu Hu is a Hematologist in Salt Lake City, Utah. Dr. Hu is highly rated in 18 conditions, according to our data. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Hu is currently accepting new patients.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

University Of Utah Hospital And Clinics

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Univ. Of Utah Hosp. Im-hematology-hematologic
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: TAA-T cells, Nivolumab
Study Phase: Phase 1
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

30 Total Publications

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Narendranath Epperla
Hematology
Expertise in
16
conditions
Dr. Narendranath Epperla
Hematology

Univ. Of Utah Hosp. Im-Hematology-Hematologic

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-3229
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Narendranath Epperla is a Hematologist in Salt Lake City, Utah. Dr. Epperla is highly rated in 16 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Epperla is currently accepting new patients.

Expertise in
21
conditions
Dr. Josef Prchal
Hematology
Expertise in
21
conditions
Dr. Josef Prchal
Hematology

University Of Utah Hospital Pathology Department

50 N Medical Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-581-2507
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Josef Prchal is a Hematologist in Salt Lake City, Utah. Dr. Prchal is highly rated in 21 conditions, according to our data. His top areas of expertise are Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant. Dr. Prchal is currently accepting new patients.

Expertise in
22
conditions
Dr. Charles Parker
Hematology
Expertise in
22
conditions
Dr. Charles Parker
Hematology

Huntsman Cancer Institute Bmt

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-2626
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Parker is a Hematologist in Salt Lake City, Utah. Dr. Parker is highly rated in 22 conditions, according to our data. His top areas of expertise are Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent Porphyria, Porphyria Cutanea Tarda, and Bone Marrow Aspiration. Dr. Parker is currently accepting new patients.

Frequently Asked Questions about Dr. Boyu Hu

How do I make an appointment with Dr. Boyu Hu?

You can book an appointment with Dr. Boyu Hu by calling their office at 801-585-3229. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Boyu Hu a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Boyu Hu is classified as an Distinguished expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Boyu Hu specialize in?

While Dr. Boyu Hu is a Hematology, they have specific expertise in Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, and Chronic B-Cell Leukemia (CBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Boyu Hu participate in research or clinical trials?

Yes. Dr. Boyu Hu has published 30 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Dr. Boyu Hu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Boyu Hu accept my insurance?

Dr. Boyu Hu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-585-3229 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hu's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile